LoMed Pain Management | Safe Narcotics for Pain | Philadelphia Pain Specialists
A Safe Narcotic Option for Pain Management.


LoMed Announcements and Updates.

Posts tagged Pain Management
LoMed Partners with LifeWIRE

In our continued mission to bring a sense of hope to our patients, we have partnered with LifeWIRE to provide a bi-directional texting program for every patient.

In this way every patient who opts in will be able to connect to us on a 24/7 basis.

Who is LifeWIRE Group?

“The LifeWIRE Messaging Platform is an integral part of a broad and continually expanding support network for on-going and long-term chronic and member wellness needs. LifeWIRE's secure cloud-based interactive software solution that creates connectivity with, and is responsive to, multiple intake and access points. The platform engages with an end user, such as a service provider, through their mobile phones through automated, pre- programmed managed exchanges which assist them providing feedback, follow-up or outreach in achieving their intended outcomes.  Responses can be free form or controlled to measure status and when responses fall outside established parameters, 3rd party notification is automatically triggered by the system.

LifeWIRE was developed under the careful guidance of some of the most senior thought leaders in the mobile health (mHealth) field. Founder Howard Rosen is a regular speaker at international symposia (HIMSS), has addressed US Congressional committees, written the guidelines for Ontario`s `Taking Ontario Mobile` policy initiative and has been called upon by the Canadian federal government to represent the country in international trade and policy meetings on health innovation. Research Director Dr. William Harms has advised and been lead investigator on research with the Veterans’ Administration, the Altarum Institute along with extensive work with Health and Human Services and 25 years of Fortune 500 senior management experience. LifeWIRE’s extended team of business leaders and partners allows us to create solutions and keep on top of changing standards across the country and around the world.”

Read more at https://lifewiregroup.com

The Evaluation of Blended Codeine Therapy for Chronic Pain at the Global Pain Clinician Summit 2018 Poster Abstracts | Pain Management Conference

Dennis J. Bonner, M.D will be presenting his research evaluating the effectiveness of Codeine preparation for the treatment of moderate to severe pain at the Global Pain Clinician Summit 2018: Transforming How We Care for People with Pain in Boston.

Posters will be presented on Friday, November 9, 2018 throughout the Summit breaks and reception.

When: Friday, November 9 - Saturday, November 10, 2018
8:00 AM
Where: Joseph B. Martin Conference Center at Harvard Medical Center
77 Avenue Louis Pasteur
NRB 133
Boston, Massachusetts  02115-5899
United States

Attend the Summit.

Comprehensive Pain Management Associates Endorse the LoMed Pain Management Program

The first casualty of the government’s war on opioid addiction and the prescription drug abuse epidemic is the 77 million people who suffer from chronic non-cancer pain. 

On October 4th 2016 the United States Drug Enforcement Administration (DEA) announced the reduction of almost every Schedule II opiate and opioid medication that may be manufactured in the United States in 2017 by 25% or more. There were additional reductions for manufacturing in 2018. This reduction greatly reduces access of opioids for pain relief and penalizes patients who are trying to cope with pain on a daily basis. 

Furthermore, the Centers for Disease Control and Prevention (CDC) created a summary of information on opioids and their oral morphine milligram equivalents to provide guidance towards preventing prescription abuse, misuse and overdose. Additionally, the CDC set a limit of 90 morphine milligram equivalents per day per patient. This limit effectively eliminates the majority of the pain relief narcotics currently being prescribed by physicians for 24-hour pain relief. 


Even though there is a legitimate clinical need, the CDC limits have made many physicians reluctant to prescribe opioids and the patients are left to suffer. 

T Baxter, LLC has created a pain relief program designed to implement precision, personalized tools maximizing patient safety as well as the required pain relief while complying with the CDC statutes. 

LoMed provides a proprietary combination of an amplified codeine with drugs that prevent withdrawal from their current opioid, dysphoria and constipation while providing 24 hours of pain relief. Also, due to the nature of codeine LoMed has little to no street value. The economic benefit of LoMed when compared to the currently prescribed opioids is significant. LoMed is ten times safer at half the cost. 

The LoMed program gives physicians the tools to individualize pain therapy based on the patient’s ability to avoid respiratory depression, consider their genetic ability to metabolize drugs and to insure there aren’t any conflicting drugs in their system. 

The program includes an in-home sleep study to determine the risk of respiratory depression, a pharmacogenomic test to determine the patient’s capacity to metabolize the LoMed proprietary medications and a quarterly toxicology test to confirm the presence of LoMed and the absence of benzodiazepines or other narcotics. 

Recently, I prescribed LoMed (120 mg of Codeine, 100 mg Vistaril) to a series of patients I have been treating for chronic non-cancer pain. Each patient successfully transitioned to LoMed without any signs of withdrawal while experiencing similar pain relief. 

Each patient was given LoMed II (Colace, Zofran and Neurontin) to prepare their system for codeine and transition from their current opioid. Twenty minutes later, the patients were given LoMed X-tra strength. The patients were monitored for an additional thirty minutes to rule out any side effects. 

In addition to the desired pain relief, the initial patient mentioned that he had greater mental clarity and did not experience any breakthrough pain. Additionally, they were able to sleep through the night. 

LoMed represents the only significant pain relief medication that successfully treats chronic non-cancer pain and complies with the CDC guidelines and a ray of hope for the 77 million patients overlooked by the government statues. 

Dr. Alexander E. Weingarten Joins the LoMed Physician Advisory Board.
Dr. Alexander E. Weingarten

Baxter, T. Inc. is proud to announce that Dr. Alexander E. Weingarten has accepted our invitation to be the chairman of the LoMed pain relief physician advisory board.

Dr. Weingarten is a partner at Comprehensive Pain Management Associates in Syosset, New York. In addition to being a past president of the New York State Pain Society; he is a board certified anesthesiologist and is board certified with the American Academy of Pain Medicine. He is also a recipient of a medical certificate in pain medicine from the American Board of Anesthesiology and has a clinical appointment at the New York Medical College.

Dr. Weingarten brings a vast experience in pain management combined with an extensive clinical background.